1. Home
  2. SAFT vs NTLA Comparison

SAFT vs NTLA Comparison

Compare SAFT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

HOLD

Current Price

$75.80

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.22

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFT
NTLA
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
986.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SAFT
NTLA
Price
$75.80
$9.22
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$19.83
AVG Volume (30 Days)
90.0K
3.4M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
4.72%
N/A
EPS Growth
15.78
N/A
EPS
5.87
N/A
Revenue
$1,231,116,000.00
$57,528,000.00
Revenue This Year
N/A
$1.96
Revenue Next Year
N/A
N/A
P/E Ratio
$13.27
N/A
Revenue Growth
12.77
33.52
52 Week Low
$67.04
$5.90
52 Week High
$84.20
$28.25

Technical Indicators

Market Signals
Indicator
SAFT
NTLA
Relative Strength Index (RSI) 41.85 44.93
Support Level $78.10 $8.94
Resistance Level $79.26 $9.62
Average True Range (ATR) 1.45 0.43
MACD -0.39 0.16
Stochastic Oscillator 0.42 44.14

Price Performance

Historical Comparison
SAFT
NTLA

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: